quinazolines has been researched along with ceritinib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 5 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Yaqub, F | 1 |
| Cho, HJ; Chung, DH; Jeon, YK; Keam, B; Kim, DW; Kim, TM; Koh, J; Lee, DS; Lee, SH; Won, JK | 1 |
| Garber, K | 1 |
| Arai, D; Betsuyaku, T; Hamamoto, J; Hayashi, Y; Hirano, T; Ishioka, K; Kawada, I; Miyawaki, M; Naoki, K; Nukaga, S; Ohgino, K; Soejima, K; Tani, T; Yasuda, H | 1 |
| Aggarwal, C; Borghaei, H | 1 |
1 review(s) available for quinazolines and ceritinib
| Article | Year |
|---|---|
Treatment Paradigms for Advanced Non-Small Cell Lung Cancer at Academic Medical Centers: Involvement in Clinical Trial Endpoint Design.
Topics: Acrylamides; Afatinib; Aniline Compounds; Carcinoma, Non-Small-Cell Lung; Clinical Trials as Topic; Crizotinib; Disease-Free Survival; Drug Approval; Endpoint Determination; Humans; Neoplasm Staging; Piperazines; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Sulfones | 2017 |
4 other study(ies) available for quinazolines and ceritinib
| Article | Year |
|---|---|
American Society of Clinical Oncology Annual Meeting 2013.
Topics: Antibodies, Monoclonal; Antineoplastic Agents; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Docetaxel; Erlotinib Hydrochloride; Female; Humans; Imidazoles; Indoles; Lung Neoplasms; Male; Medical Oncology; Multicenter Studies as Topic; Oximes; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Quinazolines; Randomized Controlled Trials as Topic; Small Cell Lung Carcinoma; Societies, Medical; Sulfones; Sunitinib; Taxoids; Treatment Outcome; Triazoles; United States | 2013 |
Concomitant ALK translocation and EGFR mutation in lung cancer: a comparison of direct sequencing and sensitive assays and the impact on responsiveness to tyrosine kinase inhibitor.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anaplastic Lymphoma Kinase; Antineoplastic Agents; Carcinoma, Non-Small-Cell Lung; Crizotinib; DNA Mutational Analysis; Female; Gefitinib; Genes, erbB-1; High-Throughput Nucleotide Sequencing; Humans; Immunohistochemistry; In Situ Hybridization, Fluorescence; Lung Neoplasms; Male; Middle Aged; Mutation; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Real-Time Polymerase Chain Reaction; Receptor Protein-Tyrosine Kinases; Sensitivity and Specificity; Sulfones; Translocation, Genetic | 2015 |
Oncologists push beyond new lung cancer genomic testing guidelines.
Topics: Anaplastic Lymphoma Kinase; Antineoplastic Agents; Crizotinib; ErbB Receptors; Erlotinib Hydrochloride; Gefitinib; Genetic Testing; Genomics; Humans; Lung Neoplasms; Medical Oncology; Molecular Targeted Therapy; Mutation; Practice Guidelines as Topic; Precision Medicine; Pyrazoles; Pyridines; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Societies, Medical; Sulfones; Translocation, Genetic | 2015 |
Overcoming EGFR Bypass Signal-Induced Acquired Resistance to ALK Tyrosine Kinase Inhibitors in ALK-Translocated Lung Cancer.
Topics: Afatinib; Anaplastic Lymphoma Kinase; Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Drug Resistance, Neoplasm; ErbB Receptors; Humans; Ligands; Lung Neoplasms; Phosphorylation; Protein Kinase Inhibitors; Pyrimidines; Quinazolines; Receptor Protein-Tyrosine Kinases; Signal Transduction; Sulfones; Translocation, Genetic | 2017 |